About the TRAILRUNNER-ALZ 3 Study
About the TRAILRUNNER-ALZ 3 Study
The TRAILRUNNER-ALZ 3 Study will see if an investigational medicine can help treat people with early Alzheimer’s disease.
You may be able to take part in this study if you:
-
Are aged 65 to 80 years old
- Have no to mild issues with your memory
-
Are willing to obtain a blood test as part of the study that checks whether you have an abnormal protein associated with Alzheimer’s disease
- Have a reliable study partner*
*A study partner is a person who knows you well and would notice any changes in your memory, mood, or behavior. This could be your spouse, partner, friend, family member, or someone whose job it is to help you. Your study partner would also need to consent to participate in the research study.
If you are interested in participating, the study doctor and staff will review additional eligibility criteria with you.
Study Overview
If you qualify to take part in the TRAILRUNNER-ALZ 3 Study, you will be randomly (that is by chance) assigned to either the investigational medicine group or the placebo group. For every 2 study participants, 1 will get investigational medicine and 1 will get placebo. Both the investigational medicine and placebo will be given as injections under the skin.
Participant duration will vary and may last up to 5 years. If the investigational medicine is safe and effective during the study, participants who received placebo may take part in an extension period and get the investigational medicine. The study team will explain this to you in more detail.
During the study you will attend visits with doctors and researchers in-person at a clinic.
Your study partner should come to study visits with you. If they cannot come to a visit, they should be available by phone for any questions or follow-up. They must be able to tell the research team about any changes in your memory and thinking.
Participant duration will vary and may last up to 5 years. If the investigational medicine is safe and effective during the study, participants who received placebo may take part in an extension period and get the investigational medicine. The study team will explain this to you in more detail.
During the study you will attend visits with doctors and researchers in-person at a clinic.
Your study partner should come to study visits with you. If they cannot come to a visit, they should be available by phone for any questions or follow-up. They must be able to tell the research team about any changes in your memory and thinking.
